Regeneron Pharmaceuticals and Sanofi announced that Dupixent (dupilumab) significantly outperformed Xolair (omalizumab) in a Phase 4 trial for treating severe chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma. The trial, involving 360 adults, was presented at the 2025 EAACI Annual Congress and showed improvements in symptoms as early as four weeks. Dupixent achieved a 1.60-point superior reduction in nasal polyp size and a 150 mL enhancement in lung function compared to Xolair, with both medications showing similar safety profiles.
The primary endpoints revealed that Dupixent resulted in an 8.0-point superior improvement in smell identification and a 31.27-point difference in peak nasal inspiratory flow. Safety data indicated adverse events occurred in 64% of Dupixent patients and 67% for Xolair, raising potential concerns for patient safety, particularly with serious adverse events recorded at 2% for Dupixent versus 4% for Xolair.
